Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a heterogeneous course and systemic involvement. It is the result of a complex pathogenic pathway that culminates in autoantibody formation. The interaction between environmental triggers and genetic susceptibility is key in this process.
Introduction

Systemic lupus erythematosus (SLE) is a chronic multi-systemic autoimmune disease with a very heterogeneous pattern of clinical and serological manifestations. Its course differs in different individuals
and is unpredictable within the same patient over time, which makes it very interesting as well as challenging to manage.
The pathogenesis of SLE is the result of interactions between genes, hormones and the environment but its precise development is mostly unknown. Recently, over 80 risk genes for the disease have been described. Certain genetic features are also associated with increased disease activity.
In the last 30 years, major efforts have been made to define some key aspects of the condition, notably disease activity and damage, using standardized indices. These tools are essential for the comparison of different cohorts, assessment of disease progression and prognosis, and measurement of response to treatment. This approach is particularly important now that new biologic drugs are beginning some encouraging signs of being effective in lupus.
This review focuses mostly on the recent advances in understanding and managing SLE.
Understanding
Epidemiology SLE is a rare disease. Estimates of its incidence are in the range 1-10 per 100,000 person-years and of prevalence from 20 to over 200 per 100,000. 1 The incidence may be increasing, probably due to higher awareness of the disease The prevalence has also been thought to be increasing, which may be reflective of an improvement in survival rates as well as its chronicity. SLE is more frequent, more severe in African, Hispanic, Chinese and Asian descendants. These patients have more haematological, serosal, neurologic and renal manifestations in general, although clinical profiles vary in specific populations. The study of the LUMINA (Lupus in Minorities: Nature vs Nurture) cohort concluded that, especially in AfricanAmerican and Hispanic populations (from Texas), there is an association with high disease activity and damage. 2 Besides ethnicity, other predictors of damage are age, disease duration, disease activity and corticosteroids.
Socioeconomic status is also associated with a worse prognosis, 2 particularly with respect to the later manifestations of the disease. Poor social support is more commonly found among ethnic minorities, which makes it difficult to distinguish their independent contributions. SLE is more frequent among women of child-bearing age in a ratio that varies between populations but is on average 10:1. Although the age of diagnosis also depends on ethnicity, it is most commonly described to be in the 3rd and 4th decades of life. Males and females show little difference in their disease manifestations or severity, though presentation at the extremes of life is associated with increased severity. 1 
Pathogenesis
There is a complex interaction between gene susceptibility, hormonal influences and environmental triggers with a breakdown of immune tolerance, resulting in autoantibody production and the consequent dysregulation of the inflammatory response leading to the induction and maintenance of the disease.
Genetic factors
The genetic component in SLE pathogenesis was first suggested by the evident concordance between monozygotic twins in 24-69% compared to 1-5% in dizygotic twins,4 and 5 and also by the different prevalence in various ethnic groups. An 8-20-fold increased risk of developing SLE has been reported in siblings of SLE patients. Some rare genetic mutations associated with familial SLE-like disease, transmitted in a Mendelian fashion, have been identified but these account for only 1-2% of cases. The discovery of these rare genetic mutations also helped understanding of some aspects of pathogenesis of this disease, since these mutations interfere with the function of the classical complement pathway (C1q, C2 and C4) and Fc gamma receptors, which are both implicated in disease pathogenesis.
In the last decade, with the development of Genome-Wide Association Study (GWAS) technology, over 80 loci with common variants have been shown to have a confirmed association with SLE. These genes lead to the formation of key proteins involved in innate and adaptive immunity. 5 Each appears to make a small contribution to the complex pathogenesis of lupus, which suggests that they work in a cumulative way.
One of the chromosomal regions having the strongest association with SLE is the human leucocyte antigen (HLA) locus, especially the class II region containing HLA-DRB1, DQA1 and DQB1.
There are also associations of some of these loci with specific clinical features (e.g. DRB1 and renal disease) 5 and serologic features (e.g. DR2 and anti-Sm antibodies, and DR3 and anti-Ro antibodies). 6 Though hormonal influences have a greater importance in determining the higher prevalence of SLE in women, some X-chromosome linked genes have been described that might contribute to this (e.g. IRAK1, its neighbour gene MECP2 and presence of CD40L). 5 In the last decade, the importance of the interferon (IFN) signature in the pathogenesis of SLE has been recognized. IFNα is a key mediator in the activation of innate response and also in the adaptive immune system (normally in response to a viral infection). It enhances natural killer-cell activity, stimulates the maturation of antigen-presenting cells, prevents apoptosis of T cells, suppresses regulatory T cells, and promotes B cell differentiation and antibody production. In patients with SLE, IFNα expression is increased in the absence of appropriate stimuli, because of the over-expression of regulating genes, and IFNα concentration is associated with disease activity. 5 Besides the growing knowledge of the genetics of SLE, post-translational modifications are likely to be contributors to the complex inheritance and incomplete concordance between homozygotic twins. In SLE, epigenetic modifications such as abnormalities in DNA methylation and histones have been reported. 5 For example, an elevated IL-6 concentration may contribute to proliferation of B cells via DNA methylation.
Environmental influences and triggers
The importance of the environment has been suggested by epidemiologic studies. The 'prevalence gradient hypothesis' describes a higher prevalence of SLE in the Afro-Caribbean population living in Europe and North America, whereas the prevalence in Western Africa is very low. 1 However, this observation may result from an environmental influence on the manifestations of SLE or from inadequate health systems in Africa that fail to recognize the condition.
Infections seem to be able to work in both ways; they can modulate the immune system protecting against autoimmunity, but can also trigger the disease. An association between SLE and Epstein-Barr virus (EBV) infection has been described in children 7 and this virus may trigger a flare due to antigenic mimicking (EBV protein EBNA-1 can cross-react with the self-antigen Ro 1 ). An association between cytomegalovirus (CMV) and SLE has also been suggested.
Oestrogens increase the risk of the disease and are a recognized trigger to flare, which probably contributes to the higher prevalence of SLE in women. Women treated with hormonal replacement therapy (but not with oral contraceptives) have a higher risk of mild-to-moderate flare, 7 and associations between SLE and early menarche, menstrual irregularities and early or surgical menopause have been described. Other environmental triggers reported include ultraviolet light, cigarette smoking and silica.
Drugs implicated in drug-induced lupus include hydralazine, D-penicillamine, minocycline, lithium and more recently TNFα blockers.
Pathologic mechanisms
The complex pathogenesis of SLE seems to involve almost every component of the immune system that culminates in antibody formation. The principal mechanisms are listed here. •An important part is played by T cells. Auto-antigen-specific T-cells have been described. T-cells stimulate B-cell proliferation and are necessary to the secretion of high-affinity class-switched IgG antibodies, in a process called T-lymphocyte help. These antibodies are strongly associated to tissue damage in SLE. 7 T regulatory cells, which suppress T helper cells and B cells, are impaired in SLE. 7 •Dysregulated apoptosis and defective clearance of cellular debris increasing auto-antigen exposure and tolerance breakdown. In SLE, apoptosis (particularly of T lymphocytes) is dysregulated in a Fas/Fas ligand-dependent pathway that is hyperexpressed and correlates with SLE activity and autoantibody concentrations. Abnormalities in the innate immune system, including phagocytes and complement, are also linked to impaired recognition and clearance of apoptotic bodies. Subsequently, abnormal prolonged exposure of nuclear antigens that undergo multiple alterations creates neoepitopes or uncovers hidden epitopes. The remaining apoptotic bodies then go through a process called secondary necrosis that leads to the release of even more nuclear material.
NET (neutrophil extracellular traps), which are a mechanism of defence against microorganisms, also play an important role in perpetuating the inflammation and exposure of dsDNA because they are not promptly degraded in SLE. The lower degradation of NET in SLE correlates with disease activity.
•Antibody formation with pathogenic potential. The presence of hyperactive and hyper-responsive Band T-cells and the prolonged exposure to nuclear antigens leads to the formation of auto-antibodies directed against nuclear structures that are the immunologic hallmark of SLE.
Auto-antibodies have been reported to be found up to 10 years before the onset of symptoms in 85% of SLE patients. (pg 8) Deposition of auto-antibodies and complement with inflammation is identified in biopsies of various tissues of patients with SLE. The most widely studied antibody is anti-double stranded DNA (anti-dsDNA), the serum concentration of which correlates with disease activity. Other antibodies have been identified in biopsies and serum from patients with SLE, and the presence of each of these correlates with specific clinical manifestations ( Table 2) .
However, the pathogenic role of the auto-antibodies in SLE is not clear. Although these antibodies are found in kidney biopsies, where they bind directly with renal cells or to circulating nuclear components, which are then deposited in the renal glomerular basement membrane (leading to inflammation), the hypothesis of secondary binding to an already inflamed tissue is not excluded. In this case, the presence of auto-antibodies would be a marker of inflammation and not a cause of it. Another suggestion is that dsDNA antibodies are actually binding to nucleosomes; in other words, dsDNA is linked to histones and the histones (which are positively charged) are responsible for binding to negatively charged regions of renal tissue -the so-called 'histone bridge theory'.
Auto-antibodies lead to the formation of immune complexes that directly induce B cells to produce more auto-antibodies and enhance the toll-like receptor-IFN1 pathway that also stimulates B cells to differentiate into plasmablasts.
It is important to bear in mind that different auto-antibodies have different specificities and sensitivities. Table 1 shows the auto-antibodies which may be present in SLE. ANA has 95% sensitive but lacks specificity. This is present up to 20% of the normal healthy population, as well as in other types of autoimmune disease, malignancies, infections and medication use. (Wandstrat et al) A higher ANA titre, especially 1:640 and above would be considered significant and may suggest the presence of an autoimmune condition. A homogenous pattern of ANA is seen in patients with SLE, and linked to anti-DNA and anti-nucleosome antibodies whereas a speckled pattern is linked to anti-ENA. Anti-Sm and antidsDNA both are rare in other rheumatic diseases and are highly specific but have low and moderate sensitivity, respectively. (Page 9) antibodies which are 3 times as common in black compared to white patients are associated with a higher mortality and morbidity. Anti-dsDNA enzyme-linked immunoassays (ELISA) is used in clinical practice to monitor lupus activity, unlike anti-Sm, the levels of which do not correlate with disease activity. DNA Crithidia is another test which may be used in the diagnostic process being more specific than the ELISA method.
Classification criteria
SLE can affect virtually any organ and system in the body. Classification criteria are a fundamental tool to ensure that a consistent definition is used in research as well as epidemiologic studies. Neuropsychiatric SLE (NPSLE) is highly diverse, comprising of central and peripheral nervous system manifestations as well as focal to more diffuse syndromes. This results in diagnostic difficulty, particularly because this may be present without derangements in the typical markers of active lupus such as anti-dsDNA and complement. Disruption in blood brain barrier has been thought to be an important factor for the development of NPSLE. Headaches are a common neurological complaint in SLE patients, and although studies have suggested that this is not more common in SLE but not specific or linked to active disease. However, it is important to assess for the presence of red flag signs suggesting a subarachnoid haemorrhage, venous sinus thrombosis and meningitis. Reduction in cognitive function, 'brain fog' as well as depression are also other common complaints in patients with SLE.
Gastrointestinal symptoms are common in SLE, and are usually mild and related to infective causes or as a side effect of treatment of SLE. Gastrointestinal manifestations of SLE, which may be due to gut vasculitis presents challenging diagnostic problems and may result in increased morbidity if not identified and treated. Lupus enteritis is a potentially fatal GI manifestation of SLE, with symptoms varying from that of an acute abdomen, pseudo-obstruction or protein-losing enteropathy. Primary biliary cirrhosis, another autoimmune disease, has been reported to occur between 0.3 and 2.4% of patients with SLE. Autoimmune hepatitis has been reported to occur in 3-10% of patients with SLE 3-10% with a higher incidence in patients juvenile SLE, coeliac disease in 0.15-2.4% of patients with SLE and PSC may also occur in SLE but this has been reported to be rare. Other autoimmune diseases may also co-exist with SLE, such as secondary Sjogren's syndrome, overlap syndromes with features of rheumatoid arthritis and scleroderma, hypothyroidism and anti-phospholipid syndrome.
The prognosis of SLE has changed markedly in the last 50 years. The 5-year survival rate has improved from 50% in the 1950s to over 90% today. 1 Improvement in prognosis is mainly due to the advances in immunosuppressive therapy, dialysis and transplantation and in general management, including anti-hypertensive drugs and statins. In addition, the recognition and management of various comorbidities, such as osteoporosis and cardiovascular disease, have improved. However, the mortality rate is still increased, with a recent meta-analysis reporting the all-cause mortality to be 2.6 times that of the general population. In the last 40 years it has been recognized that cardiovascular disease is a major cause of death in SLE. Urowitz et al. described this phenomenon in 1976, reporting a bimodal mortality in SLE. In the first phase disease activity is the main cause of death, while later on in the course of the disease the main cause of death is cardiovascular disease.8 and 9
Classical cardiovascular (CV) risk factors contribute to this increased risk, notably smoking (20% of patients in most cohorts continue to smoke), hypertension and dyslipidemia. In addition, the sustained inflammation in autoimmune diseases leads to accelerated atherosclerosis. Thromboembolic events are also increased in SLE.
Patients with SLE have been found to have an increased risk of certain malignancies. In a large multi-centre international study by Bernatsky et al, SLE patients were found to be 3 times more likely to develop haematological malignancies, in particular, non-Hodgkin's lymphoma and leukaemia, and there is also a small increased risk in lung, thyroid and vulval cancers. The pre-cancerous stage, cervical dysplasia has been reported to have a higher incidence in patients with SLE, especially in patients who have been treated with cyclophosphamide. This highlights the importance of SLE patients adhering to national cervical screening programmes. Interestingly, there is a lower risk of developing breast, endometrial and ovarian cancers in women and prostate cancers in men. Pregnancy morbidity is higher in patients with SLE, which include miscarriages, intrauterine growth restriction and pre-term birth, with the presence of lupus nephritis and anti-phospholipid syndrome increasing this risk further. The risk of neonatal heart block is estimated to be 2% with anti-Ro antibody positive mothers, increasing further to 15% in the next pregnancy if neonatal heart block was present in the previous pregnancy. Well-controlled lupus for at least 6 months prior to conception optimizes pregnancy outcomes.
The susceptibility to infections has been thought to be due to an impaired immune response, with the most common infection being respiratory tract infections. This is further compounded by increased lupus activity, hypocomplementaemia, leucopaenia, steroid use with doses above 7.5mg, immunosuppressants such as cyclophosphamide. The mortality rate of patients with SLE due to infections has been reported to be early 5 times that of the general population. The BILAG index measures the activity in each organ system in five categories (A, B, C, D and E). Each item is classified by the clinician as not present, improving, the same, worse or new, based upon the principle of the 'physician's intention to treat'. 10 The BILAG index is the only tool that measures activity in each specific organ or system. Other indices specific for just one organ have been validated (e.g. the Cutaneous Lupus Erythematosus Disease Activity and Severity Index; CLASI). The other indices are global and provide a final score for the whole body's disease activity.
SLEDAI is the most commonly used of the global scores indices. It measures activity in the last 10 days (though it has been validated for the last 30 days). It is simpler than BILAG but has some flaws; it does not distinguish partial improvement or worsening of symptoms, and it is less sensitive to change than other instruments. 10 11 This definition emphasizes that the increase in disease activity should be measurable and should lead to the consideration of changing the treatment. Nevertheless, it may still be difficult to distinguish mild flares from some non-lupus symptoms and progressive organ damage with this definition.
Other global indices have been validated, namely ECLAM (European Consensus Lupus Activity
Measurement), LAI (Lupus Activity Index) and SLAM (Systemic Lupus Activity Measurement, and its revised version SLAM-R); it is worth mentioning that the inclusion of patients' subjective symptoms in SLAM make it very sensitive to changes important to patients though it may be less accurate.
Damage is another essential feature to measure. SLICC/ACR -Systemic Lupus International
Collaborating Clinics/American College of Rheumatology damage index (SDI) was designed to capture permanent change after the diagnosis of SLE regardless of the cause, secondary to the disease itself or secondary to treatment. The manifestation must be irreversible or should be present for 6 months. This tool has important prognostic properties. Rahman et al. showed, importantly, that early damage measured by this index is associated with greater mortality in the first decade of follow-up. 12 The patient's perception of SLE is not captured by activity or damage indices. For clinical trials on belimumab a new index was used, the SLE responder index (SRI) that used SELENA-SLEDAI to determine global improvement, BILAG to evaluate each organ and system and physician's global assessment to guarantee that there was not a worsening in patient's overall condition.
Treatment
The treatment of SLE depends on the organ and systems involved and the severity of the disease, and can vary from topical medicines for skin disease or NSAIDs for musculoskeletal disease to aggressive systemic immunosuppression. As already reported, the prognosis of SLE has greatly improved, probably due to new drugs that have been designed and tested, and also because of a better general management. It is now clear that associated diseases like osteoporosis and cardiovascular disease should be prevented and diagnosed and treated early.
Osteoporosis is strongly associated with SLE and the World Health Organization (WHO)
suggests regular dual X-ray absorptiometry (DXA) for a correct diagnosis of osteoporosis, to determine the fracture risk and monitor the effect of treatment.
Patients with SLE should also be screened for the presence of CV risk factors and CV disease. 9 Modifiable risk-factors such as hypertension and hyperlipidaemia should be identified and concurrently Patients should be advised to reduce exposure to strong sunlight and to use adequate sun protection (SPF 50+) especially those with cutaneous manifestations.
Corticosteroids
Corticosteroids have been the 'core' treatment for SLE and other autoimmune diseases since they were first used in rheumatoid arthritis in 1949. Their mechanism of action consists in the modification of genomic and non-genomic pathways, the latest being activated in higher dosages (prednisolone >30 mg/day) leading to immunosuppressive and anti-inflammatory effects.
The dose and route of administration of these drugs varies according to the organ(s) affected and the severity of the disease. Their mode of use is mostly determined by the physician's experience; there are no guidelines describing the ideal regimen. In mild disease there is usually a response to prednisolone 5-15 mg/day or equivalent, and a sparing agent or antimalarial can also be used. In life-threatening and organ-threatening disease, methylprednisolone is used as a pulse intravenous therapy. Some patients do not respond sufficiently to corticosteroid agents and in some manifestations of SLE a combination with an immunosuppressive drug is more effective.
European League Against Rheumatism (EULAR) has published guidelines on low-dose glucocorticoid therapy. They recommend close monitoring of the adverse effects, especially in high-dose, since most are dose-dependent.
Hydroxychloroquine
The immunomodulating properties of antimalarial drugs and their benefit in rheumatic disease have been known since World War II. In the last 20 years new evidence has shown that this drug is suitable for many manifestations of SLE: it prevents, and can be used to treat, articular and skin flares; it protects against ultraviolet light; it improves sicca symptoms; it is associated with milder disease; and it gives a more favourable cardiovascular profile in many different ways (reduces cholesterol, reduces the risk of diabetes, reduces the risk of development of carotid plaque and it has antithrombotic properties). In patients with renal disease it also facilitates the response to mycophenolate mofetil (MMF) 13 and ACR's 2012 guidelines suggest that it should be given to every lupus patient with nephritis. It was also shown that it prevents damage in the kidneys and central nervous system 14 and, probably as a result of all of this, it reduces mortality. 15 Although hydroxychloroquine is generally a safe drug, prescribers have to be aware of risks of ocular toxicity, and initiate appropriate ophthalmology surveillance for this our practice is to seek a detailed ophthalmology review after 5 years on the drug [at a dose of 400mg/day].
Cardiotoxicity is a serious but rare adverse effect, with case reports describing hydroxychloroquineinduced cardiomyopathy.
Immunosuppressives
Other immunosuppressive drugs have been used in severe manifestations of SLE. Lupus nephritis is the most common life-threatening manifestation and has been the working field for the research into the effects of new drugs.
The National Institutes of Health (NIH) studies in the 1980s established that cyclophosphamide (CYC)-containing regimens were more effective than corticosteroids alone when treating lupus nephritis.
Importantly, in 2002, the Euro-Lupus Nephritis trial demonstrated that a low-dose CYC regimen was as effective as the high-dose NIH regimens and had fewer (although not statistically significant) adverse effects; 16 it is currently the preferred CYC regimen but, because CYC is very toxic even in low-dose regimens and because a significant percentage of patients are still resistant, new drugs have been tested.
The Aspreva Lupus Management Study (ALMS) trial 17 showed that MMF is a good option for the induction phase because it is as effective as CYC. It also has fewer adverse effects than CYC and is more effective than azathioprine (AZA). It is important to bear in mind that cyclophosphamide and MMF are contraindicated in pregnancy and breastfeeding, and therefore, AZA, though inferior to MMF, is a good option during pregnancy or if the preservation of fertility is a concern. 18 CYC has been used to treat myositis, and gastrointestinal and pulmonary manifestations. MMF is also effective in refractory haematological and dermatological manifestations. 19 In the ALMS trial it was shown that CYC and MMF are similarly effective in controlling extra-renal disease (in a group of patients with renal lupus). 20 For neuropsychiatric lupus there is a lack of evidence concerning the best treatment option but corticosteroids alone or in combination with CYC or AZA are recommended; other drugs are used in refractory cases.
Both tacrolimus and ciclosporin, via inhibition of calcineurin, inhibit the production of cytokines and lymphocyte proliferation, especially T-helper cells. There is some evidence that tacrolimus is effective in the induction treatment for lupus nephritis. Ciclosporin may be used as a corticosteroid-sparing drug in patients with normal renal function.
Biologic therapy
As the pathogenesis of lupus is becoming better understood, the biologics have an increased role to play.
The most logical and widely used option is B cell depletion achieved by direct B cell elimination or inhibition of B cell survival agents.
Belimumab is a human monoclonal IgG1 that binds to BLyS (also known as BAFF, B-cell Rituximab's corticosteroid-sparing effect is of great importance. After Ezeonyeji et al. 21 showed the benefit of early treatment with rituximab, Condon et al. have recently reported the result of the first 50 patients treated with the Rituxilup protocol, using rituximab and MMF but no oral corticosteroids, with very good efficacy. 22 Disappointingly, the two randomized controlled studies, EXPLORER and LUNAR, failed to show benefit from adding rituximab to the ongoing immunosuppressive treatment in extra-renal and renal lupus patients, respectively. Inadequate trial design almost certainly played a part, as patients with severe and refractory disease were excluded and a high dose of corticosteroids was maintained, obscuring the efficacy of rituximab and its corticosteroid sparing effect.
Ofatumumab is a fully humanized monoclonal antibody against CD20 antigen which is used to treat CLL and which has been shown to be efficacious in rheumatoid arthritis. This has been demonstrated in case studies to be effective in treating SLE and is a promising option for cases where rituximab is not tolerated. BELONG, a phase III trial investigating ocrelizumab, another anti-CD20 agent in class III/IV lupus nephritis was terminated early when a higher risk of serious infections was observed in the ocrelizumab group in combination with MMF. 
Key points:
1. SLE is a complex disease with multi-systemic involvement.
2. SLE is more common in females.
3. There is a higher prevalence of SLE in patients with African heritage, with more severe disease and poorer clinical outcomes. 4 . Classification criteria and tools to measure disease activity should be used in clinical practice.
5. The SLICC classification criteria (2012) are more sensitive than the revised ACR criteria; requiring at least one clinical and one immunological feature to be present. 
c) Renal biopsy
A renal biopsy will be necessary to identify the aetiology of proteinuria.
d) Urine protein:creatinine ratio and microscopy for casts
This is important as part of the work up in this lady, but this will not provide information regarding the aetiology of the proteinuria. e) CT kidney/ureter/bladder A CT scan is used to identify for causes of obstructive uropathy such as renal calculi but in this patient's case, will not be useful to identify the aetiology of her renal dysfunction.
3.
A 50-year-old gentleman with psoriatic arthritis comes for a review in the rheumatology outpatients. He is currently treated with a TNF blocking drug, etanercept for the last six months after having failed combination disease-modifying therapy with methotrexate and sulfasalazine.
He reports that he is unsure that his medication is controlling his disease as he has started to develop arthralgia. He has reported fatigue lately, with mouth ulcers and a photosensitive facial rash. His ANA, previously negative, was repeated in your clinic which shows 1:640 and otherwise has a normal auto-antibody screen. He has normal complement levels. What is the most likely 
